Switzerland· 66424001
Kevzara
A sarilumab product containing sarilumabum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Sarilumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AC14 (sarilumab), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 8 of them publish a price we can compare per daily dose
Sarilumab · ATC L04AC14
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of sarilumab costs, country by country.
Normalised to the WHO defined daily dose (14.3 mg), so markets compare like for like.
- Switzerland: $60.91 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Sarilumab · price per daily dose (14.3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$60.91
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- sarilumabum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L04AC14
- ATC class
- Sarilumab
- Defined daily dose
- 14.3 mg, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806642400162 StkCHF 1059.8
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
190 interactions on record for sarilumab.
Graded by severity as the source publishes them — 39 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sarilumab · interactions on record
190 records
- 39 severe
- 144 moderate
- 7 minor
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sarilumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKEVZARASanofi Winthrop Industrie, Gentilly
- SwedenKevzara 150 mg Injektionsvätska, lösning i förfylld injektionspennaSanofi Winthrop Industrie
- NetherlandsKevzara 150 mg, oplossing voor injectie in voorgevulde penSanofi Winthrop Industrie
- IcelandKevzaraSanofi Winthrop Industrie
- BelgiumKevzara 150 mgSanofi Winthrop Industrie
- FinlandKevzaraSanofi Winthrop Industrie
- United StatesKEVZARASanofi-Aventis U.S. LLC
- SpainKEVZARA 150 MG SOLUCION INYECTABLE EN JERINGA PRECARGADASanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kevzara
- Liechtenstein · Kevzara
- Norway · Kevzara
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/92a7c1c9-7c2e-4ba7-a99f-a2a6730acdd4 GET /v1/drugs/92a7c1c9-7c2e-4ba7-a99f-a2a6730acdd4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "sarilumabum 150 mg",
"valid_from": "2023-09-01",
"limitations": "[{\"description\":\"Nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation und Genehmigung des Vertrauensarztes des Krankenversicherers zur Behandlung der aktiven rheumatoiden Arthritis bei erwachsenen Patienten, die auf die Behandlung mit einem konventionellen synthetischen DMARD (disease modifying anti-rheumatic drugs) oder einem Tumornekrosefaktor (TNF)-Hemmer nicht ausreichend angesprochen haben.<br>\\nBei einer Unverträglichkeit auf Methotrexat oder wenn die Behandlung mit Methotrexat ungeeignet ist kann Kevzara als Monotherapie verabreicht werden.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2023-09-01\",\"validTo\":null}]",
"galenic_form": "Inj Lös 150 mg/1.14 ml Fertigspritze",
"therapeutic_area": null,
"sl_inclusion_date": "2018-09-01",
"self_retention_pct": 10
}See everything about sarilumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.